Johannes Waldschmidt

22PUBLICATIONS
166CO-AUTHORS
Gene and molecular therapyMolecular targetsHaematological tumoursPredictive and prognostic markersRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Jul 06, 2026
Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

|Jun 25, 2026
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

|Apr 02, 2026
Promoter hypomethylation drives ABCB1-mediated carfilzomib resistance in multiple myeloma.

Seungbin Han, Larissa Haertle, Umair Munawar

|Mar 31, 2026
Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.

Umair Munawar, Johanna Thurner, Silvia Nerreter

|Mar 26, 2026
Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy.

Sofie-Katrin Kadel, Lukas Scheller, Alexander M Leipold

|Mar 25, 2026
Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myeloma.

Johannes Waldschmidt, David Fandrei, Judith S Hecker

Pageof 4

Frequent Collaborators

11 joint publications

Klaus Martin Kortüm

9 joint publications

Leo Rasche

9 joint publications

Hermann Einsele

6 joint publications

Marc-Steffen Raab